Table 1.

Inclusion, exclusion and withdrawal criteria

Inclusion	Exclusion
18 years of age or older	Non-aneurysmal subarachnoid haemorrhage.
Anterior circulation aneurysm rupture	Multiple ruptured aneurysms.
Patients who have undergone surgical intervention	Patients with congestive heart failure.
Absence of rebleeding or new intracranial haemorrhage on postintervention CT scan	Severe aneurysmal subarachnoid haemorrhage (Hunt-Hess grade V).
Consent to study participation	Active pathological bleeding.
	Allergy to cilostazol.
	Positive pregnancy test.
	Coagulopathy not caused by anticoagulant use.
	History of haemorrhagic complications (gastrointestinal bleeding, and so on).
	Uncontrolled or severe comorbidity that would qualify as an absolute contraindication for cilostazol.
	Patients requiring anticoagulant treatment following intervention (eg, stent-assisted coiling or flow-diverting stent obliteration of aneurysm). Exception: patients who require the use of aspirin as determined by the staff member performing the coil embolisation for thromboembolic event protection due to a small amount of coil extrusion from the aneurysm neck will be allowed to be included into the trial.

Criteria for discontinuing follow-up: subject wishing to terminate participation in the study at any time throughout his/her participation.